ReviewAustralian prescriber2018
Medical management of metastatic prostate cancer.
Review in Australian prescriber, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 14 citations in OpenAlex.
- The effect of unusual presentation on delayed diagnosis of prostate cancer: a case series.Journal of medical case reports · 2024Article
- A Novel Interaction between Chemokine and Phosphoinositide Signaling in Metastatic Prostate Cancer.Medical research archives · 2023Article
- A Retrospective Study of the Effect of Metformin on Patients with Metastatic Prostate Cancer.Clinical Medicine Insights. Oncology · 2023Article
- Development of [Pharmaceutics · 2021Article
- Novel therapeutic compounds for prostate adenocarcinoma treatment: An analysis using bioinformatic approaches and the CMap database.Medicine · 2020Article
- Darolutamide for prostate cancer.Australian prescriber · 2020Review
- Apalutamide for prostate cancer.Australian prescriber · 2019Review
- Liquid Biopsy in Oligometastatic Prostate Cancer-A Biologist's Point of View.Frontiers in oncology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
androgen deprivation therapy has an important role in the medical treatment of advanced and metastatic prostate cancerTHE TREATMENT OF METASTATIC PROSTATE CANCER IS INFLUENCED BY WHETHER THE PATIENT’S DISEASE HAS PROGRESSED ON ANDROGEN DEPRIVATION THERAPY OR NOT IT IS CONSIDERED TO BE CASTRATE-RESISTANT DISEASE IF THE CANCER HAS PROGRESSED DESPITE ADEQUATE SUPPRESSION OF ANDROGENS: CHEMOTHERAPY USING DOCETAXEL OR CABAZITAXEL AND ANTI-ANDROGEN DRUGS SUCH AS ABIRATERONE AND ENZALUTAMIDE CAN BE USED TO TREAT CASTRATE-RESISTANT DISEASE RADIUM-223 IS AN OPTION FOR PATIENTS WITH BONY METASTASES: METASTATIC CASTRATE-RESISTANT PROSTATE CANCER IS NOW CONSIDERED A CHRONIC ILLNESS AS THE LIFE EXPECTANCY OF PATIENTS HAS ALMOST DOUBLED DUE TO THE NEW TREATMENTS GENERAL PRACTITIONERS ARE THEREFORE MORE LIKELY TO ENCOUNTER PATIENTS WITH DISEASE- AND TREATMENT-RELATED COMPLICATIONS:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.